SIAG
LCTX icon

Safeguard Investment Advisory Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Safeguard Investment Advisory Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5
Closed – – 426
2020
Q4 		$0 Buy
+5
New +$7 ﹤0.01% 751

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Safeguard Investment Advisory Group's LCTX Position: Q1 2021 in Review

Safeguard Investment Advisory Group sold out of Lineage Cell Therapeutics (LCTX) in Q1 2021, closing a stake of 5 shares.

Safeguard Investment Advisory Group first reported a position in LCTX in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 102 funds tracked by Wall St. Rank hold LCTX as of Q1 2021.

  • Safeguard Investment Advisory Group reported no remaining Lineage Cell Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Safeguard Investment Advisory Group sold 5 Lineage Cell Therapeutics shares in Q1 2021.
  • Safeguard Investment Advisory Group first reported a position in Lineage Cell Therapeutics in Q4 2020 and held it in 1 quarter.
  • Safeguard Investment Advisory Group's Lineage Cell Therapeutics position peaked at $0 in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2021.

Based on Safeguard Investment Advisory Group's 13F filing for Q1 2021, filed 10 May 2021.